Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
75°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vera Therapeutics Inc Cl A
(NQ:
VERA
)
39.30
+0.18 (+0.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vera Therapeutics Inc Cl A
< Previous
1
2
3
4
5
Next >
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
August 08, 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
May 31, 2024
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Vera Therapeutics: Q4 Earnings Insights
March 20, 2024
Via
Benzinga
(VERA) - Analyzing Vera Therapeutics's Short Interest
January 31, 2024
Via
Benzinga
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
May 29, 2024
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024
May 09, 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Could This Stock Be the Next Biotech Buyout?
April 13, 2024
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Via
The Motley Fool
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...
Via
Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Via
Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 11, 2024
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning!
Via
InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
April 11, 2024
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023
March 20, 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
February 02, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
January 26, 2024
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.
Via
Benzinga
What's Going On With Vera Therapeutics Stock Today?
January 26, 2024
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.
Via
Benzinga
Exposures
Product Safety
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 26, 2024
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 26, 2024
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Via
Benzinga
Topics
Government
Exposures
Political
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
January 26, 2024
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
January 25, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today?
January 25, 2024
Vera Therapeutics' 72-week data from Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR.
Via
Benzinga
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
January 25, 2024
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 25, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via
Benzinga
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
January 25, 2024
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
January 25, 2024
Via
Benzinga
Why Vera Therapeutics Stock Soared by 22% This Week
January 12, 2024
Executive changes and a bullish analyst take combined to boost sentiment on the company.
Via
The Motley Fool
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...
Via
Benzinga
Exposures
Product Safety
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
December 18, 2023
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.